Phase I/II – First Administration

454 trials 191 recruiting

Filter these 454 trials by condition, country, sponsor and more.

Open in Search →

FTIH study to investigate the safety and preliminary efficacy of the DNA-repair inhibitor GSK4418959 alone or in combination with other anti… Ended

2024-519721-37-00 Neoplasms, Colorectal 2025-08-06
Phase I/II study of AGuIX nanoparticles with radiotherapy plus concomitant Temozolomide in the treatment of newly diagnosed glioblastoma Ended

2024-517114-15-00 newly diagnosed gliblastoma 2025-03-07
Inmmunotherapy with peripheral blood, autologous, a dult T cells, expanded and transduced (gene modified) with a lentiviral vector expressin… Ended

2024-515624-36-00 Refractary or relapse non-Hodgkin T CD30+ lymphoma. 2024-12-17
Study of JDQ443 in advanced cancer with a specific mutation (G12C) of the KRAS gene Ended

2023-508073-87-00 Advance solid tumors harboring the KRAS G12C mutation 2024-11-14
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants with… Ended

2023-508697-28-00 Frontotemporal Dementia (FTD) 2024-11-13
Phase I/II Safety and Tolerability Study of striatal administration of AB-1001 in adult subjects with Early Manifest Huntington's Disease (H… Ended

2024-510895-18-00 Huntington's disease 2024-11-07
A Phase 1/2 Study of MK-2870 plus EV plus Pembrolizumab in la/mUC Ended

2023-506387-14-00 Advanced Urothelial Carcinoma 2024-09-24
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women with Recurrent Vulvovaginal Candidiasis: A Randomize… Ended

2023-507527-28-00 Recurrent vulvovaginal candidiasis 2024-09-16
A Phase I/II clinical trial with SENS-501 in children suffering from severe to profound hearing loss due to Otoferlin (OTOF) mutations Ended

2023-504466-28-00 Bilateral severe to profound hearing loss due to Otofer 2024-09-04
Phase I/II study of ANV600 single agent or in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1) Ended

2023-509633-39-00 Advanced solid tumours 2024-08-06
A Phase I, open-label, multi-center exploratory safety and efficacy study with PSMA, SSTR2 and GRPR targeted radioligand therapy in metastat… Ended

2023-505655-43-00 Metastatic neuroendocrine prostate cancer 2024-07-29
Allogeneic Tissue Engineering (Nanostructured Artificial Human Cornea) in Patients With Corneal Trophic Ulcers in Advanced Stages, Refractor… Ended

2024-515481-13-00 Corneal trophic ulcers refractory to conventional treat 2024-07-05
Study of Subretinally Injected AAVB-081 in Patients with Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa Ended

2024-518489-29-00 Usher Syndrome Type 1B (USH1B) Retinitis Pigmenotsa 2024-07-01
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours Ended

2023-506228-10-00 Pancreatic Ductal Adenocarcinoma 2024-06-27
Cell-mediated skipping of exon 51 for the genetic correction of dystrophin, based upon a single injection of autologous mesoangioblasts (MAB… Ended

2024-514860-14-00 Duchenne Muscular Dystrophy 2024-06-27
A trial to find out how safe REGN7075 is and how well it works in combination with cemiplimab for participants with advanced cancers Ended

2022-501234-37-00 Solid Tumours 2024-05-07
A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent gl… Ended

2023-508278-26-01 glioblastoma 2024-04-05
A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intrav… Ended

2023-506737-30-00 Duchenne Muscular Dystrophy 2024-03-08
A Trial of Lu AG13909 in Participants with Congenital Adrenal Hyperplasia Ended

2023-503711-15-00 Congenital adrenal hyperplasia 2024-01-25
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION717 in Patie… Ended

2023-503355-98-00 Prion diseases 2024-01-24
Phase 1/2, Open label & double-blind randomized placebo-controlled study to assess the feasibility of BGC101 (EnEPC) in the treatment of per… Ended

2024-516665-36-00 Peripherial arterial disease (PAD) & Chronic-Limb Threa 2024-01-23
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab, TransCon TLR7/8 Agonist, or … Ended

2023-509143-27-00 Locally advanced or metastatic solid tumor malignancies 2023-11-27
Therapeutic vaccination: Phase I / II clinical study on patients randomized blinded to the experimental vaccine or placebo regimen. we want … Ended

2024-514581-39-00 HIV Infection 2023-11-08
SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mH… Ended

2023-507672-52-00 PSMA-positive metastatic hormone sensitive prostate can 2023-11-07